Valérie Cochen De Cock’s research while affiliated with IMT Mines Alès and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (129)


Symptomatic Treatment of REM Sleep Behavior Disorder (RBD): A consensus from the International RBD Study Group - Treatment and Trials Working Group
  • Article

May 2025

·

45 Reads

Sleep Medicine

·

Roneil Malkani

·

Isabelle Arnulf

·

[...]

·


Salivary Alpha-Synuclein to Differentiate Parkinson’s Disease from Drug Induced Parkinsonism and Controls Using ELISA

December 2024

·

14 Reads

Background: Alpha-synuclein is a promising biomarker for Parkinson’s disease (PD).


Lack of Epistatic Interaction of SNCA with APOE in Synucleinopathies
  • Preprint
  • File available

August 2024

·

88 Reads

Two recent studies suggested that the APOE ε4 haplotype was associated with increased α-synuclein pathology in cell and mouse models. Genetic variants in the SNCA region have strong association with Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and idiopathic REM Sleep Behavior Disorder (iRBD), while APOE is a genetic risk determinant for only DLB. To determine if genetic-level interactions between SNCA and APOE exists that can explain the protein-level association, we investigated the genotypic interaction of APOE and SNCA in cohorts of PD, DLB, and iRBD. We analyzed genome-wide association study (GWAS) data from 5,229 PD patients and 5,480 controls, 2,610 DLB patients and 1,920 controls, and 1,055 iRBD patients and 3,667 controls. We used logistic regression interaction models across all 3 cohorts independently between the 1) top GWAS signals of SNCA SNPs and APOE haplotypes, 2) SNP x SNP and 3-way SNP interaction across the entire coding region plus 200kb flanking each gene. No significant interactions were found to be associated with any of the synucleinopathies after correction for multiple testing. Our results do not support a role for genetic interactions between APOE and SNCA across PD, DLB, and iRBD. Since the tested genetic variants affect the expression and function of these proteins, it is likely that any interactions between them does not affect the risk of PD, DLB and iRBD.

Download


Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy

March 2024

·

194 Reads

·

15 Citations

Objective: To apply a machine learning analysis to clinical and presynaptic dopaminergic imaging data of patients with rapid eye movement (REM) sleep behavior disorder (RBD) to predict the development of Parkinson disease (PD) and dementia with Lewy bodies (DLB). Methods: In this multicenter study of the International RBD study group, 173 patients (mean age 70.5 ± 6.3 years, 70.5% males) with polysomnography-confirmed RBD who eventually phenoconverted to overt alpha-synucleinopathy (RBD due to synucleinopathy) were enrolled, and underwent baseline presynaptic dopaminergic imaging and clinical assessment, including motor, cognitive, olfaction, and constipation evaluation. For comparison, 232 RBD non-phenoconvertor patients (67.6 ± 7.1 years, 78.4% males) and 160 controls (68.2 ± 7.2 years, 53.1% males) were enrolled. Imaging and clinical features were analyzed by machine learning to determine predictors of phenoconversion. Results: Machine learning analysis showed that clinical data alone poorly predicted phenoconversion. Presynaptic dopaminergic imaging significantly improved the prediction, especially in combination with clinical data, with 77% sensitivity and 85% specificity in differentiating RBD due to synucleinopathy from non phenoconverted RBD patients, and 85% sensitivity and 86% specificity in discriminating PD-converters from DLB-converters. Quantification of presynaptic dopaminergic imaging showed that an empirical z-score cutoff of −1.0 at the most affected hemisphere putamen characterized RBD due to synucleinopathy patients, while a cutoff of −1.0 at the most affected hemisphere putamen/caudate ratio characterized PD-converters. Interpretation: Clinical data alone poorly predicted phenoconversion in RBD due to synucleinopathy patients. Conversely, presynaptic dopaminergic imaging allows a good prediction of forthcoming phenoconversion diagnosis. This finding may be used in designing future disease-modifying trials.


Partial endorsement of: “Video-polysomnography procedures for diagnosis of rapid eye movement sleep behavior disorder (RBD) and the identification of its prodromal stages: Guidelines from the International RBD Study Group” by the World Sleep Society

August 2023

·

45 Reads

·

3 Citations

Sleep Medicine

Updated guidelines for the video-polysomnography (vPSG) procedures for diagnosing rapid eye movement sleep behavior disorder (RBD) and the identification of its prodromal stages have recently been proposed by the Neurophysiology Working Group of the International RBD Study Group (IRBDSG). These guidelines were selected for review by a World Sleep Society (WSS) Parasomnias Task Force and the WSS International Sleep Medicine Guidelines Committee. A survey was completed by sleep society leaders and prominent sleep clinicians and researchers in 31 WSS member countries across six continents, focused on sleep technologist training and certification; extent of public/private health insurance coverage for the vPSG evaluation of RBD; extent of hospital-based sleep-technologist-attended overnight vPSG studies; availability of video during PSG studies; and sufficient specification of PSG machines to record and analyze REM sleep without atonia. The findings from this survey indicated that most health systems and medical communities across WSS member countries would not be capable of implementing the proposed more stringent guidelines, which would then strongly interfere with the diagnosis of RBD in a large portion of patients who would not be able to receive the required (often repeated) vPSG evaluation. Therefore, the WSS can only partially endorse the updated guidelines and concludes that the current International Classification of Sleep Disorders-3rd edition diagnostic criteria for RBD should still be retained as the standard reference for the diagnosis of RBD, and that further discussion across all members of the IRBDSG should take place to ensure the feasibility of any future proposed changes.


Neuropsychological testing in iRBD at baseline. (A) Pooled results for each neuropsychological test in all iRBD participants using a meta‐analysis of single means. Detailed results by study center are shown in Figure S1. (B) Mean testing results sub‐grouped by phenoconversion status. TMT, trail making test.
Cumulative incidence of dementia phenoconversion in iRBD stratified by impaired baseline testing (tests of attention and executive domains). Results are presented according to baseline neuropsychological test (impaired z‐score ≤ −1.5). Hazard ratios according to competitive risk regression are shown, adjusting for age, sex, education, depression, and study center, with 95% confidence intervals in parentheses. TMT, trail making test.
Cumulative incidence of dementia phenoconversion in iRBD stratified by impaired baseline testing (tests of memory, language, visuospatial domains, and MCI). Results are presented according to baseline neuropsychological test (impaired z‐score ≤ −1.5). Hazard ratios according to competitive risk regression are shown, adjusting for age, sex, education, depression, and study center, with 95% confidence intervals in parentheses. MCI, mild cognitive impairment.
Annual progression of neuropsychological testing in iRBD. Neuropsychological testing and assessed up to 10 years prior to phenoconversion or censoring. Individual dots represent each participant; solid lines represent estimated progression by linear mixed‐effect modeling; shaded areas represent 95% confidence intervals; horizontal dotted lines indicate thresholds for reduced cognitive performance (z‐score < zero) and impaired performance (z‐score ≤ −1.5). MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment; TMT, Trail Making Test.
Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study

July 2023

·

146 Reads

·

26 Citations

INTRODUCTION Isolated/idiopathic rapid eye movement sleep behavior disorder (iRBD) is a powerful early predictor of dementia with Lewy bodies (DLB) and Parkinson's disease (PD). This provides an opportunity to directly observe the evolution of prodromal DLB and to identify which cognitive variables are the strongest predictors of evolving dementia. METHODS IRBD participants (n = 754) from 10 centers of the International RBD Study Group underwent annual neuropsychological assessment. Competing risk regression analysis determined optimal predictors of dementia. Linear mixed‐effect models determined the annual progression of neuropsychological testing. RESULTS Reduced attention and executive function, particularly performance on the Trail Making Test Part B, were the strongest identifiers of early DLB. In phenoconverters, the onset of cognitive decline began up to 10 years prior to phenoconversion. Changes in verbal memory best differentiated between DLB and PD subtypes. DISCUSSION In iRBD, attention and executive dysfunction strongly predict dementia and begin declining several years prior to phenoconversion. Highlights Cognitive decline in iRBD begins up to 10 years prior to phenoconversion. Attention and executive dysfunction are the strongest predictors of dementia in iRBD. Decline in episodic memory best distinguished dementia‐first from parkinsonism‐first phenoconversion.


HLA association in isolated REM sleep behavior disorder.
HLA in isolated REM sleep behavior disorder and Lewy body dementia

July 2023

·

113 Reads

·

5 Citations

Synucleinopathies-related disorders such as Lewy body dementia (LBD) and isolated/idiopathic REM sleep behavior disorder (iRBD) have been associated with neuroinflammation. In this study, we examined whether the human leukocyte antigen (HLA) locus plays a role in iRBD and LBD. In iRBD, HLA-DRB1*11:01 was the only allele passing FDR correction (OR = 1.57, 95% CI = 1.27-1.93, p = 2.70e-05). We also discovered associations between iRBD and HLA-DRB1 70D (OR = 1.26, 95%CI = 1.12-1.41, p = 8.76e-05), 70Q (OR = 0.81, 95%CI = 0.72-0.91, p = 3.65e-04) and 71R (OR = 1.21, 95%CI = 1.08-1.35, p = 1.35e-03). Position 71 (pomnibus = 0.00102) and 70 (pomnibus = 0.00125) were associated with iRBD. Our results suggest that the HLA locus may have different roles across synucleinopathies.


Figure 2. Individual data and summary statistics of measures sensitive to coordination rigidity in three activities of daily living: gait (Studies 1 and 2), quiet standing (Study 1), and speech (Study 2). To display on a common scale, each dependent variable was first normalized (z-score across the groups). The qualitative difference in movement is shown on top. In the PD group, vertical accelerations during free overground walking exhibited lower log-divergence rate (λ), anterior-posterior postural fluctuations while maintaining standing posture with eyes open were more regular (SEN), the voice amplitude dynamics were more predictable (LVOICE).
Figure 2
Figure 3. The star coordinates plot visualizes high-dimensional data for classification problems. p=VTx+b projects the 11-D normalized feature space (dashed lines) onto 2-D. The y-component of the axes corresponds to the β coefficients of those features in the classifier. The second column of V contains those weights and, with the addition of b, the bias in the classifier, it maps feature vectors x to f ̂ (x), where PD if f ̂ (x)>0 (grey line). The weights are summarized statistically in Appendix D. The x-component in the plot (the first column of V) is arbitrary, used for better visualization of the data. True status is color-coded and allows to see false positives (HC classified as PD) and false negatives (PD classified as HC) located on the wrong side of the classification line.
Figure B1. Mean (+/-95% confidence intervals) of the multiscale entropy shown separately per condition, measurement axis, and group.
Coordination Rigidity in the Gait, Posture, and Speech of Persons with Parkinson’s Disease

May 2023

·

195 Reads

·

3 Citations

Journal of Motor Behavior

Parkinson's disease (PD) is associated with reduced coordination abilities. These can result either in random or rigid patterns of movement. The latter, described here as coordination rigidity (CR), have been studied less often. We explored whether CR was present in gait, quiet stance, and speech-tasks involving coordination among multiple joints and muscles. Kinematic and voice recordings were used to compute measures describing the dynamics of systems with multiple degrees of freedom and nonlinear interactions. After clinical evaluation, patients with moderate stage PD were compared against matched healthy participants. In the PD group, gait dynamics was associated with decreased dynamic divergence-lower instability-in the vertical axis. Postural fluctuations were associated with increased regularity in the anterior-posterior axis, and voice dynamics with increased predictability, all consistent with CR. The clinical relevance of CR was confirmed by showing that some of those features contribute to disease classification with supervised machine learning (82/81/85% accuracy/sensitivity/specificity).


Night‐Time Apomorphine Infusion: Who Are the Best Candidates?

May 2023

·

36 Reads

·

4 Citations

Background We recently demonstrated in a randomized controlled trial (APOMORPHEE, NCT02940912) that night‐time only subcutaneous apomorphine infusion improves sleep disturbances and insomnia in patients with advanced Parkinson's disease and moderate to severe insomnia. Objectives To identify the best candidates for receiving night‐time only subcutaneous apomorphine infusion in routine care. Methods In this post‐hoc analysis of APOMORPHEE, we compared the characteristics of patients according to whether they chose to continue night‐time only subcutaneous apomorphine infusion at the end of the study period or not. Results Half of the patients (22/42) chose to continue the treatment. Off duration (day or night), painful Off dystonia, and insomnia severity at baseline were associated with night‐time only apomorphine continuation. Multivariate analysis retained only Off duration as an independent predictor of continuation. Conclusions The best candidates for night‐time only apomorphine are patients with severe and prolonged Off periods (day or night) and severe insomnia.


Citations (61)


... SARS-CoV-2 infection was significantly associated with higher adjusted risk for dyspnea, fatigue, and fall in PD patients up to three and a half years post-pandemic. Although many of these symptoms occur in PD patients, they are not exclusive to those with PD [50][51][52][53][54]. Our cohort consisted of a large proportion of minorities. ...

Reference:

Impact of COVID‐19 on long‐term outcomes in Parkinson's disease
Sleep and sleep disorders in people with Parkinson's disease
  • Citing Article
  • June 2024

The Lancet Neurology

... Subsequently, the label "clinically isolated", which would apply to RBD patients who do not have overt motor or cognitive signs or symptoms, has been proposed as a replacement for the term "idiopathic" [2]. Nevertheless, at the time of diagnosis, most iRBD patients show mild motor symptoms, mild cognitive impairment (MCI), autonomic and olfaction dysfunctions, and neuroimaging abnormalities (mostly abnormal presynaptic dopaminergic imaging, typically on SPECT, i.e., DaT-SPECT), which are suggestive of incipient alpha-synucleinopathy [3][4][5]. Indeed, the vast majority of iRBD patients will eventually receive a clinical diagnosis of Parkinson's disease (PD) or dementia with Lewy bodies (DLB), and a minority of multiple system atrophy (MSA) [5]. Research criteria for prodromal PD (pPD) [6] and prodromal DLB (pDLB) [7] were defined based on the acknowledgment that these disorders have a long prodromal stage before the emergence of overt Parkinsonism and/or dementia. ...

Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy
  • Citing Article
  • March 2024

... Minor sleep disturbances often occur in the early stages of PD, while a broader spectrum of sleep-related symptoms characterizes advanced PD [4]. Polysomnographic (PSG) evaluations in advanced PD show disruptions consistent with affected neural pathways, particularly involving connections between sleep-regulating nuclei and regions, such as the substantia nigra [5]. ...

Partial endorsement of: “Video-polysomnography procedures for diagnosis of rapid eye movement sleep behavior disorder (RBD) and the identification of its prodromal stages: Guidelines from the International RBD Study Group” by the World Sleep Society
  • Citing Article
  • August 2023

Sleep Medicine

... In our study, a reduced DTI-ALPS in iRBD was associated with low processing speed, as assessed with the oral version of the SDMT, and decreased semantic fluency. Reduced processing speed is considered the most prominent neuropsychological feature in iRBD 33,[44][45][46][47] , strongly contributing to executive functioning deficits 33 , which are well-established markers of conversion into dementia forms of LBD 48,49 . Relevantly, slowness in information processing has been related with altered resting-state functional dysconnectivity in posterior cortical regions 44 . ...

Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study

... A pesar de ello, en el análisis post hoc del estudio APOMORPHEE, de los 42 pacientes que completaron el estudio, sólo 22 optaron por continuar el tratamiento. Los otros 20 (casi la mitad) no lo continuaron [14]. Teniendo en cuenta que el período de tratamiento fue inferior a tres semanas, parece que la mayoría de los pacientes que discontinúa el tratamiento con apomorfina en infusión subcutánea lo hace al principio, período que no tenemos en cuenta para los análisis de nuestro estudio. ...

Night‐Time Apomorphine Infusion: Who Are the Best Candidates?
  • Citing Article
  • May 2023

... The most effective region identified in our study closely aligns with the sweet spot previously identified for optimally addressing rigidity and bradykinesia in PwPD (superior, posterior, medial) 16 . The alleviation of rigidity and bradykinesia symptoms can enhance a patient's ability to initiate and effectively exert movement, thereby improving walking ability [30][31][32] . This may explain why the most effective region for the mean value of spatial gait parameters overlaps with the sweet spot for relieving clinical symptoms such as rigidity and bradykinesia. ...

Coordination Rigidity in the Gait, Posture, and Speech of Persons with Parkinson’s Disease

Journal of Motor Behavior

... Each electrode contact recording was then re-referenced to the uppermost contact. For our model, we used periodic activity in different frequency bands: theta (3-7 Hz), alpha (8)(9)(10)(11)(12), lower beta (13)(14)(15)(16)(17)(18)(19)(20) and upper beta (21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35). We refined the power spectral density at each recording site by removing 1/f components (dashed lines), which facilitated the isolation of distinct oscillatory activity peaks (solid lines) (Fig. 3b). ...

Symptoms assessment and decision to treat patients with advanced Parkinson’s disease based on wearables data

npj Parkinson s Disease

... Patients with abnormal baseline MoCA phenoconverting to DLB likely far exceed 65%, supported by the facts that average baseline MoCA was 22.6 (± 3.6) versus 25.8 (± 2.6) for those who phenoconverted to DLB versus PD contrasted with the average baseline MMSE of 26.4 (± 3.2) versus 27.8 (± 1.7) for DLB versus PD phenoconverters 19 . In this study and others, motor symptoms and signs had no bearing on phenoconversion 19,76 . Given our aim of investigating prodromal PD, we biased our recruitment toward likely PD-phenoconverters by including only patients who were cognitively intact based on assessment by a movement disorder neurologist and a MoCA > 23/30 (actual 26.9/30 ± 0.5). ...

Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study

Brain

... In the past decades, the ubiquitous presence of pleiotropy has been further substantiated, emphasizing that a variant or gene has an effect on multiple categories of traits 16,17 . While previous studies on GBA1 have mostly focused on one neurological disease or similar neurological phenotypes [18][19][20][21] , recent research reveals that GBA1-associated traits extend beyond neurological conditions, including blood urea nitrogen (BUN), uric acid, hemoglobin (Hb), and hematocrit (HCT) 22 . Nevertheless, investigations into the non-neurological effects of GBA1 remain limited, leaving substantial gaps in our understanding of the broader spectrum of GBA1associated phenotypes. ...

Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects

... "Live" video capture of a DEB during vPSG strongly supports the diagnosis; however, the majority of patients do not enact dreams during a singlenight recording. 11 By contrast, repeated brief, simple movements during REM sleep are frequent in RBD and can be observed every night, [12][13][14] but the use of video data for diagnosing and distinguishing RBD from other sleep disorders is not fully established. A recent study proposed a machine learning (ML) classifier based on the automated analysis of movements during REM sleep using a 3D time-of-flight camera in a sleep laboratory and yielded accuracies up to 86.6% for distinguishing RBD from other sleep conditions using only 2 features of rate (frequency) and ratio (burden) of movements. ...

The polysomnographic diagnosis of REM sleep behavior disorder: to change or not to change, that is the question
  • Citing Article
  • December 2022

Sleep